RegeneRx allowed to advance RGN-259 into phase III for neurotrophic keratopathy Oct. 21, 2014 No Comments
A team of scientists at Novartis synthesize new complement C5 convertase inhibitors Oct. 8, 2014 No Comments
Interim phase II results for squalamine lactate plus ranibizumab in neovascular AMD Oct. 8, 2014 No Comments
Novel selective prostanoid EP2 receptor agonist shows promise in preclinical studies Oct. 7, 2014 No Comments
FDA expands approval for Eylea Injection in treating macular edema following retinal vein occlusion Oct. 7, 2014 No Comments
RSS